ClinicalTrials.gg
CompletedNCT01891409Updated Jan 19, 2015

Use of the Shang Ring Circumcision Device in Boys Below 18 Years Old in Kenya

An interventional study of Male circumcision using the Shang Ring device in Human Immunodeficiency Virus, sponsored by EngenderHealth. Completed at 1 site in Kenya. Open to male participants aged 1 Month to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-19.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by EngenderHealth · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
1 Month to 17 Years
Sex
Male
01

Study summary

A proof of concept study to evaluate the feasibility of using the Shang Ring, a novel male circumcision device across all childhood age groups namely infants (under 1), 1-5 age group, 6-12 age group and the 13-17 age group. The study will evaluate the safety, efficacy and course of wound healing when using the Shang Ring technique across the four childhood age groups.

Read the detailed description

A proof of concept study to evaluate the feasibility of using the Shang Ring, a novel male circumcision device across all childhood age groups namely infants (under 1), 1-5 age group, 6-12 age group and the 13-17 age group. The study will evaluate efficacy, procedure time, difficulties during surgery and post-operative events shall be assessed. To evaluate safety, the investigators will clinically observe for adverse events during the course of healing. The investigators will also evaluate to length of time taken for complete healing to be achieved.

02

Conditions studied

  • Human Immunodeficiency Virus

Browse trials for

Keywords

  • HIV prevention
  • Male Circumcision
  • Children
  • Childhood
  • Shang Ring
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,035 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 306 are open to participants now.

This study's enrollment of 80 is below the median of 96 across 2,251 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

EngenderHealth is the lead sponsor of 4 studies on the registry; none are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be accompanied by the parent or legally acceptable representative (LAR), who freely consents for participation of the child into the study;
  • Assent from participant 7 years of age and above who understand study procedure;
  • Aged between 1 month and 17 years(inclusive);
  • Body weight of more than 2.5 kgs and penile shaft more than 1 cm in length.
  • Must be in good general health;
  • Must be free of genital ulcerations or other visible signs of STI (on examination);
  • Parent or LAR and if possible the client must be able to understand study procedures and requirements of study participation;
  • Parent or LAR must agree to return the client to the study site for the full schedule of follow-up visits after his circumcision;
  • Parent or LAR must have a cell phone or access to a cell phone; and,
  • Parent or LAR must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.

Exclusion criteria

Exclusion Criteria:

  • Has a known allergy or sensitivity to lidocaine or other local anesthesia;
  • Takes a medication that would be a for elective surgery, such as an anticoagulant or ;
  • Has known bleeding/clotting disorder (e.g. hemophilia);
  • Has any congenital genitourinary abnormality;
  • Has an active genital infection, anatomic abnormality or other condition (e.g. severe obesity, diabetes or sickle cell anemia), which in the opinion of the surgeon, prevents the man from undergoing a circumcision as part of this study; or
  • Is currently participating in another biomedical research study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Other
    Single arm

    Single arm study study for use of Shang Ring device for male circumcision in children

    Device: Male circumcision using the Shang Ring device

Interventions

  • DeviceMale circumcision using the Shang Ring device

    Also known as: Shang ring male circumcision device

06

What researchers measure

Primary outcomes

  1. To evaluate safety when using the Shang Ring technique across the 4 age groups ranging from infants to adolescents.

    Documentation of adverse events based on clinical exam findings

    Time frame: 42 days after circumcision

Secondary outcomes

  1. To evaluate efficacy when using the Shang Ring technique across the 4 age groups ranging from infants to adolescents.

    To evaluate efficacy, procedure time, peri- and postoperative surgical complications, and problems with use of the device will be assessed.

    Time frame: 42 days after circumcision

  2. To evaluate the course of wound healing when using the Shang Ring technique across the 4 age groups ranging from infants to adolescents.

    Evaluation of the course of healing and length of time required for complete healing will be based on clinical exam findings.

    Time frame: 42 days after circumcision

  3. To determine the acceptability of the Shang Ring device by the participants (or their parents)

    Clients and/or parents shall be interviewed on their experience with the Shang Ring during their participation in the study.

    Time frame: 42 days after circumcison

  4. To evaluate the ease of use of the Shang Ring technique across the 4 age groups ranging from infants to adolescents

    To evaluate the ease of use of the Shang Ring device, clinicians shall be interviewed on the difficulties they faced with using the device and their perception about use of the device relative to conventional surgical approaches

    Time frame: 42 days after circumcision

07

Study locations

1 site
  • Homa Bay District Hospital
    Homa Bay, Kenya
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2013
First posted
Jul 3, 2013
Start
Jul 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Last update
Jan 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01891409
Lead sponsor
EngenderHealth
Collaborators
Weill Medical College of Cornell University, Kenya National AIDS & STI Control Programme, Kenya Ministry of Health
Responsible party
Sponsor
First posted
Jul 3, 2013
Start date
Jul 2013
Primary completion
Nov 2013
Completion
Nov 2013
Last update
Jan 19, 2015

Study contacts

Quentin Awori, MBChB, CPI
principal investigator · EngenderHealth

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion